- Research Services
- Capabilities
- About Us
- Resources
- Contact Us
Radiation Countermeasures - Acute Radiation Syndrome (ARS)
Radiation Countermeasures – ARSUtilize our preclinical rodent models of total body irradiation (TBI), TBI with long bone protection, or targeted gastrointestinal (GI) radiation to assess radiation countermeasures in the treatment of acute radiation syndrome (ARS), GI-ARS, and/or survival. Having served as a contractor on several BARDA and DoD grants, we provide the expertise needed to guide and execute these complex projects.
At BioModels, you can assess your novel therapeutics for efficacy and mechanism of action in our established models of Acute Radiation Syndrome (ARS) to address unmet clinical needs for patients. ARS refers to an acute illness caused by exposure to a high dose of penetrating radiation to the body which can affect three distinct areas of the body, the bone marrow, the gastrointestinal tract (GI-ARS), and the cardiovascular/central nervous system (CNS). We offer well-established mouse models of both total body irradiation (TBI) and gastrointestinal tract-focused toxicity through shielding of the long bones to assess critical disease mechanisms and phenotypes.
Our literature-validated experimental endpoints include:
Study Models
There is a critical need to develop therapies to prevent radiation exposure related deaths resulting from gastrointestinal and bone marrow toxicities. Currently, only potassium iodide is recognized as a radio-protectant in this context, protecting only the thyroid from ingested radioactive iodine. At BioModels, evaluate your test compounds for efficacy in targeting the GI tract, the bone marrow, or both in our total body irradiation mouse model. Non-anesthetized animals are placed in a pie-shaped multi-chamber plastic restrainer and placed inside the radiation source. A single, precise dose of total body irradiation (x-ray) at varying levels is administered to groups of mice to generate a dose response curve. The radiation dose can be titrated to achieve the lethal dose appropriate for your study. The main endpoints of the model include survival and body weight change. Histological endpoints can also be examined to address the mechanism of action.
C57Bl/6 animals that receive TBI (x-ray) are weighed daily, and body weight change as compared to Day 0 are calculated and shown over the course of the study for each radiation (x-ray) dose level.
Survival of C57Bl/6 mice that receive TBI (x-ray) is tracked daily over the course of the study.
Close
Exposure to high levels of ionizing radiation results in toxicities of the gastrointestinal (GI) tract that often lead to death. There is a critical need to develop therapies that treat the damaged GI tract to reduce or prevent exposure-related deaths. At BioModels, evaluate your test compounds for efficacy in targeting the GI tract in our validated GI-directed acute radiation syndrome mouse model. In this model, one hind limb of an anesthetized animal is protected using a lead shield while a single, precise dose of total body irradiation (x-ray) is delivered. The main endpoints of the model include survival and body weight change. Histological endpoints can also be examined to address the mechanism of action.
C57Bl/6 animals that receive TBI with long bone protection are weighed daily, and body weight change as compared to Day 0 are calculated and shown over the course of the study for each radiation (x-ray) dose level.
Survival of C57Bl/6 mice that receive TBI (x-ray) with long bone protection is tracked daily over the course of the study.
C57Bl/6 mice receive TBI (x-ray) with long bone protection. Representative images show the epithelial architecture of the villi and crypts of normal jejunum (A) and damaged jejunum (B) 4 days after exposure to radiation.
Close
